Does Evolocumab Improve Heart Health in Type 1 Diabetes?
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
PICO
Structured summariesStructured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
Can Weekly Semaglutide Replace Mealtime Insulin in Type 2 Diabetes?
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
Is Automated Insulin Delivery Safe and Effective for Young Children?
In children aged 2-6 years with type 1 diabetes, the MiniMed 780G in auto mode improved time in range and HbA1c over manual mode with suspend-before-low, meeting non-inferiority with superiority. PICO summary and expert commentary.
Semaglutide and Walking Distance in PAD with Type 2 Diabetes: A STRIDE Subgroup Analysis
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
Does Tirzepatide Weight Loss Improve Quality of Life?
A secondary patient-reported-outcomes analysis of the SURMOUNT-1 phase 3 trial finds tirzepatide improved health-related quality of life versus placebo in adults with obesity, with larger gains at greater weight loss. PICO summary and expert commentary.
Tirzepatide vs Semaglutide for Obesity in Type 2 Diabetes: An Indirect Comparison
An industry-sponsored indirect treatment comparison suggesting tirzepatide 10 and 15 mg achieve greater weight, BMI and HbA1c reduction than semaglutide 2.4 mg in type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
ECC5004/AZD5004: First-in-Human Phase 1 Findings
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.
Does Automated Insulin Delivery Improve Sleep in Youth with High HbA1c?
A 13-week randomised trial found automated insulin delivery sharply lowered HbA1c in youth with type 1 diabetes but objectively reduced sleep efficiency and increased night-time wakefulness. PICO summary and expert commentary.
Does Home Telemedicine Plus Health Education Improve Blood Sugar in Older Adults?
A 6-month randomised trial in older adults with type 2 diabetes found home telemedicine plus Health Belief Model education cut HbA1c by 0.42% more than usual care. PICO summary and expert commentary.
Is a Tubeless Open-Source Insulin System Safe and Effective at Home?
In 28 AID-naive adults with type 1 diabetes, a tubeless open-source hybrid loop (AndroidAPS) raised time in range to 75.6 percent versus 60.4 percent on sensor-augmented pump therapy without added hypoglycaemia. PICO summary and expert commentary.